ECSP10010112A - Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa - Google Patents
Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasaInfo
- Publication number
- ECSP10010112A ECSP10010112A EC2010010112A ECSP10010112A ECSP10010112A EC SP10010112 A ECSP10010112 A EC SP10010112A EC 2010010112 A EC2010010112 A EC 2010010112A EC SP10010112 A ECSP10010112 A EC SP10010112A EC SP10010112 A ECSP10010112 A EC SP10010112A
- Authority
- EC
- Ecuador
- Prior art keywords
- cinasa
- compounds
- tienopirimidine
- pirazolopirimidine
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a compuestos de tienopirimidina y pirazolopirimidina de las Fórmulas (Ia) y (IIa), (Ia)(IIa)o una de sus sales farmacéuticamente aceptables, en las que las variables constituyentes son como se definen en el presente documento, a composiciones que comprenden los compuestos y a procedimientos de preparación y uso de los compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98033207P | 2007-10-16 | 2007-10-16 | |
US2759508P | 2008-02-11 | 2008-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP10010112A true ECSP10010112A (es) | 2010-08-31 |
Family
ID=40345078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010010112A ECSP10010112A (es) | 2007-10-16 | 2010-04-16 | Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa |
Country Status (26)
Country | Link |
---|---|
US (1) | US8129371B2 (es) |
EP (1) | EP2212333A1 (es) |
JP (1) | JP2011500702A (es) |
KR (1) | KR20100083170A (es) |
CN (1) | CN101883774A (es) |
AP (1) | AP2010005234A0 (es) |
AR (1) | AR068898A1 (es) |
AU (1) | AU2008312631A1 (es) |
BR (1) | BRPI0817681A2 (es) |
CA (1) | CA2702838A1 (es) |
CL (1) | CL2008003061A1 (es) |
CO (1) | CO6321257A2 (es) |
CR (1) | CR11373A (es) |
DO (1) | DOP2010000118A (es) |
EA (1) | EA201000484A1 (es) |
EC (1) | ECSP10010112A (es) |
IL (1) | IL205109A0 (es) |
MA (1) | MA31884B1 (es) |
MX (1) | MX2010004260A (es) |
NI (1) | NI201000060A (es) |
PA (1) | PA8799101A1 (es) |
PE (1) | PE20091384A1 (es) |
TN (1) | TN2010000171A1 (es) |
TW (1) | TW200922593A (es) |
WO (1) | WO2009052145A1 (es) |
ZA (1) | ZA201003430B (es) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1953417B (zh) * | 1996-09-04 | 2010-12-29 | 英特托拉斯技术公司 | 一种从用户站点向外部站点发布使用数据的方法 |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
ES2460517T3 (es) | 2005-07-25 | 2014-05-13 | Emergent Product Development Seattle, Llc | Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20 |
KR101571027B1 (ko) | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
CA2710194C (en) | 2007-12-19 | 2014-04-22 | Amgen Inc. | Inhibitors of p13 kinase |
CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
TW201004963A (en) * | 2008-07-03 | 2010-02-01 | Targacept Inc | Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands |
RU2473549C2 (ru) * | 2008-07-31 | 2013-01-27 | Дженентек, Инк. | Пиримидиновые соединения, композиции и способы применения |
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
KR101634833B1 (ko) | 2008-10-22 | 2016-06-29 | 어레이 바이오파마 인크. | TRK 키나아제 억제제로서 치환된 피라졸로[1,5a] 피리미딘 화합물 |
KR101430424B1 (ko) | 2009-01-08 | 2014-08-14 | 쿠리스 인코퍼레이션 | 아연 결합 모이어티를 갖는 포스포이노시티드 3-키나제 억제제 |
EP2419432B9 (en) * | 2009-04-17 | 2016-02-17 | Wyeth LLC | Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
JP5781066B2 (ja) * | 2009-05-27 | 2015-09-16 | ジェネンテック, インコーポレイテッド | p110δに対して選択的な二環式ピリミジンPI3K阻害剤化合物及び使用方法 |
CN102480961A (zh) * | 2009-06-24 | 2012-05-30 | 健泰科生物技术公司 | 与含氧杂环稠合的嘧啶化合物、组合物和使用方法 |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
US20110021515A1 (en) * | 2009-07-24 | 2011-01-27 | Takeda Pharmaceutical Company Limited | Dihyrofuropyrmindine compounds |
KR101147550B1 (ko) | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물 |
KR101469334B1 (ko) * | 2009-11-12 | 2014-12-04 | 에프. 호프만-라 로슈 아게 | N-9-치환된 퓨린 화합물, 조성물 및 사용 방법 |
BR112012011147A2 (pt) * | 2009-11-12 | 2021-09-08 | F.Hoffmann-La Roche Ag | Composto, composição farmacêutica e uso de um composto. |
WO2011078795A1 (en) * | 2009-12-21 | 2011-06-30 | S*Bio Pte Ltd | Bridged morpholino substituted purines |
EP2525659B1 (en) | 2010-01-19 | 2019-02-27 | Merck Sharp & Dohme Corp. | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS |
CN102821767A (zh) | 2010-02-03 | 2012-12-12 | 西格诺药品有限公司 | Lkb1突变作为对tor激酶抑制剂的敏感性的预测生物标记的鉴定 |
CA2793778A1 (en) | 2010-04-05 | 2011-11-13 | Wyeth Llc | Biomarkers for p13k-driven cancer |
EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
ES2685171T3 (es) | 2010-06-14 | 2018-10-05 | The Scripps Research Institute | Reprogramación de células a un nuevo destino |
MX2013005826A (es) * | 2010-11-24 | 2013-08-27 | Exelixis Inc | Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion. |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
WO2012099581A1 (en) | 2011-01-19 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Dihydrofuropyrimidine compounds |
CN105039520A (zh) | 2011-08-03 | 2015-11-11 | 西格诺药品有限公司 | 作为lkb1状态的预测性生物标志物的基因表达谱的鉴定 |
FR2985257B1 (fr) * | 2011-12-28 | 2014-02-14 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
WO2013113097A1 (en) * | 2012-01-31 | 2013-08-08 | Beta Pharma Canada Inc. | Cyclic molecules as bruton's tyrosine kinase inhibitors |
WO2013152717A1 (zh) * | 2012-04-10 | 2013-10-17 | 上海昀怡健康管理咨询有限公司 | 稠合嘧啶类化合物,其制备方法,中间体,组合物和应用 |
CN103374021B (zh) * | 2012-04-21 | 2015-10-28 | 通化济达医药有限公司 | 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂 |
CN105062961A (zh) | 2012-05-23 | 2015-11-18 | 弗·哈夫曼-拉罗切有限公司 | 获得和使用内胚层和肝细胞的组合物和方法 |
CN103450204B (zh) * | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途 |
ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
JP6382946B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ,エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
PE20160041A1 (es) | 2013-04-17 | 2016-01-28 | Signal Pharm Llc | FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA |
TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用tor激酶抑制劑組合療法以治療癌症之方法 |
CA2908957C (en) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
CA2909625C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
TWI631950B (zh) | 2013-04-17 | 2018-08-11 | 標誌製藥公司 | 藉二氫吡𠯤并吡𠯤治療癌症 |
EP2986321A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
ES2657451T3 (es) | 2013-04-19 | 2018-03-05 | Incyte Holdings Corporation | Heterocíclicos bicíclicos como inhibidores del FGFR |
JP6401250B2 (ja) | 2013-05-29 | 2018-10-10 | シグナル ファーマシューティカルズ,エルエルシー | 7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((trans)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン、その固体形態の医薬組成物、及びその使用方法 |
KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
JP6441910B2 (ja) | 2013-09-30 | 2018-12-19 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用 |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
MX2016014878A (es) * | 2014-05-14 | 2017-03-08 | Pfizer | Pirazolopiridinas y pirazolopirimidinas. |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
DK3699181T3 (da) | 2014-11-16 | 2023-03-20 | Array Biopharma Inc | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
CA2999138C (en) | 2015-09-21 | 2024-05-21 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
BR112018008357A2 (pt) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas |
FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
RU2751767C2 (ru) | 2016-04-04 | 2021-07-16 | Локсо Онколоджи, Инк. | Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида |
LT3458456T (lt) | 2016-05-18 | 2021-02-25 | Loxo Oncology, Inc. | (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamido gavimas |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
SG11201912403SA (en) | 2017-06-22 | 2020-01-30 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
CN108358949A (zh) * | 2018-03-01 | 2018-08-03 | 南京法恩化学有限公司 | 一种2,4-二氯噻吩并[3,2-d]嘧啶的制备方法 |
CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
JP2021523118A (ja) | 2018-05-04 | 2021-09-02 | インサイト・コーポレイションIncyte Corporation | Fgfr阻害剤の塩 |
CN110850012B (zh) * | 2018-08-21 | 2022-07-08 | 四川弘远药业有限公司 | 一种1-(2,3-二氯苯基)哌嗪盐酸盐及其有关物质的检测方法 |
BR112021015353A2 (pt) * | 2019-02-06 | 2021-10-05 | Venthera, Inc. | Inibidores de fosfoinositídeo 3-cinase tópicos |
CN111646995B (zh) * | 2019-03-04 | 2023-03-21 | 四川大学 | 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
CN109824701B (zh) * | 2019-03-26 | 2021-08-13 | 武汉工程大学 | 一种吡啶并噻唑类化合物及其制备方法和应用 |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP3800188A1 (en) | 2019-10-02 | 2021-04-07 | Bayer AG | Substituted pyrazolopyrimidines as irak4 inhibitors |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JP2023505257A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤の誘導体 |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
CN113278015B (zh) * | 2021-05-31 | 2022-05-13 | 云南大学 | 一种荧光探针及其制备方法和应用 |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100345830C (zh) * | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
-
2008
- 2008-10-15 KR KR1020107010683A patent/KR20100083170A/ko not_active Application Discontinuation
- 2008-10-15 MX MX2010004260A patent/MX2010004260A/es not_active Application Discontinuation
- 2008-10-15 EA EA201000484A patent/EA201000484A1/ru unknown
- 2008-10-15 CN CN2008801190434A patent/CN101883774A/zh active Pending
- 2008-10-15 EP EP08839537A patent/EP2212333A1/en not_active Withdrawn
- 2008-10-15 JP JP2010530074A patent/JP2011500702A/ja not_active Withdrawn
- 2008-10-15 AP AP2010005234A patent/AP2010005234A0/xx unknown
- 2008-10-15 BR BRPI0817681 patent/BRPI0817681A2/pt not_active Application Discontinuation
- 2008-10-15 US US12/251,712 patent/US8129371B2/en not_active Expired - Fee Related
- 2008-10-15 CA CA2702838A patent/CA2702838A1/en not_active Abandoned
- 2008-10-15 AU AU2008312631A patent/AU2008312631A1/en not_active Abandoned
- 2008-10-15 WO PCT/US2008/079940 patent/WO2009052145A1/en active Application Filing
- 2008-10-16 TW TW097139718A patent/TW200922593A/zh unknown
- 2008-10-16 CL CL2008003061A patent/CL2008003061A1/es unknown
- 2008-10-16 AR ARP080104520A patent/AR068898A1/es unknown
- 2008-10-16 PE PE2008001780A patent/PE20091384A1/es not_active Application Discontinuation
- 2008-10-16 PA PA20088799101A patent/PA8799101A1/es unknown
-
2010
- 2010-04-15 IL IL205109A patent/IL205109A0/en unknown
- 2010-04-15 NI NI201000060A patent/NI201000060A/es unknown
- 2010-04-15 CR CR11373A patent/CR11373A/es not_active Application Discontinuation
- 2010-04-16 TN TN2010000171A patent/TN2010000171A1/fr unknown
- 2010-04-16 MA MA32778A patent/MA31884B1/fr unknown
- 2010-04-16 DO DO2010000118A patent/DOP2010000118A/es unknown
- 2010-04-16 EC EC2010010112A patent/ECSP10010112A/es unknown
- 2010-04-20 CO CO10046199A patent/CO6321257A2/es not_active Application Discontinuation
- 2010-05-14 ZA ZA2010/03430A patent/ZA201003430B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2010004260A (es) | 2010-04-30 |
ZA201003430B (en) | 2011-02-23 |
CA2702838A1 (en) | 2009-04-23 |
BRPI0817681A2 (pt) | 2015-04-14 |
DOP2010000118A (es) | 2010-06-30 |
PA8799101A1 (es) | 2009-05-15 |
TW200922593A (en) | 2009-06-01 |
JP2011500702A (ja) | 2011-01-06 |
AR068898A1 (es) | 2009-12-16 |
CL2008003061A1 (es) | 2009-01-09 |
IL205109A0 (en) | 2010-11-30 |
EP2212333A1 (en) | 2010-08-04 |
CO6321257A2 (es) | 2011-09-20 |
NI201000060A (es) | 2010-10-04 |
PE20091384A1 (es) | 2009-09-09 |
CN101883774A (zh) | 2010-11-10 |
US20090098086A1 (en) | 2009-04-16 |
AP2010005234A0 (en) | 2010-04-30 |
AU2008312631A1 (en) | 2009-04-23 |
TN2010000171A1 (fr) | 2011-11-11 |
CR11373A (es) | 2010-05-03 |
WO2009052145A1 (en) | 2009-04-23 |
EA201000484A1 (ru) | 2010-12-30 |
KR20100083170A (ko) | 2010-07-21 |
MA31884B1 (fr) | 2010-12-01 |
US8129371B2 (en) | 2012-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP10010112A (es) | Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa | |
CO6321259A2 (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis | |
CR20110216A (es) | Derivados de ácido 1-amino-2-ciclobutiletilborónico | |
CR20160015A (es) | Compuestos de éster boronato y composiciones farmacéuticas de los mismos | |
ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
UY32049A (es) | Inhibidores de cmet | |
ECSP10010015A (es) | Inhibidores de proteasoma | |
SV2010003662A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081 | |
CL2011000917A1 (es) | Compuestos derivados de tioamida; sus metodos de preparacion y uso de los compuestos para el tratamiento de enfermedades endoparasitarias. | |
UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
CL2011001967A1 (es) | Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico. | |
UY30291A1 (es) | Piridin(3,4-b)pirazinonas | |
CL2011001331A1 (es) | Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo. | |
DOP2006000017A (es) | Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso | |
ECSP10010532A (es) | Tiazolil-dihidro-indazoles | |
CO6382113A2 (es) | Compuestos quimicos | |
CR11449A (es) | Productos intermedios gsm | |
CO6460760A2 (es) | Tia-triaza-ciclopentazulenos | |
CU20100068A7 (es) | Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y p13 cinasa | |
CU20100148A7 (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis | |
CO6321260A2 (es) | Derivados aromaticos de oxima como inhibidores de hsp90 |